These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 6765525)
1. The U.S. "new patient" and "transfer" studies. Galloway JA; Peck FB; Fineberg SE; Spradlin CT; Marsden JH; Allemenos D; Ingulli-Fattic J Diabetes Care; 1982; 5 Suppl 2():135-9. PubMed ID: 6765525 [TBL] [Abstract][Full Text] [Related]
2. Treatment with human insulin (recombinant DNA) in diabetic subjects pretreated with pork or beef insulin: first results of a multicenter study. Beyer J; Enzmann F; Lauerbach M; Althoff P; Bachmann W; Brandstetter K; Cordes U; Dannehl A; Düntsch G; Haas R Diabetes Care; 1982; 5 Suppl 2():140-8. PubMed ID: 6765526 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the activity profiles of two fixed combinations of regular/NPH human insulin (recombinant DNA) of different compositions with a fixed regular/NPH porcine insulin combination (PPI) in insulin-dependent diabetic individuals. Sailer D; Ludwig T; Kolb S Diabetes Care; 1982; 5 Suppl 2():57-9. PubMed ID: 6765542 [TBL] [Abstract][Full Text] [Related]
4. A double-blind crossover trial comparing human insulin (recombinant DNA) with animal insulins in the treatment of previously insulin-treated diabetic patients. Clark AJ; Wiles PG; Leiper JM; Knight G; Adeniyl-Jones RO; Watkins PJ; Ward JD; MacCuish AC; Keen H; Jones RH Diabetes Care; 1982; 5 Suppl 2():129-34. PubMed ID: 6765523 [TBL] [Abstract][Full Text] [Related]
5. Comparative study of NPH human insulin (recombinant DNA) and pork insulin in diabetic subjects: preliminary report. Mirouze J; Monnier L; Richard JL; Gancel A; Soua KB Diabetes Care; 1982; 5 Suppl 2():60-2. PubMed ID: 6765543 [TBL] [Abstract][Full Text] [Related]
6. Crossover study with human insulin (recombinant DNA) in type I diabetic subjects. Landgraf R; Kammerer S; Bock T; Smolka B; Ladik T; Enzmann F; Landgraf-Leurs MM Diabetes Care; 1982; 5 Suppl 2():39-42. PubMed ID: 6765538 [TBL] [Abstract][Full Text] [Related]
7. Comparative study of NPH human insulin (recombinant DNA) and NPH bovine insulin in diabetic subjects. Marre M; Tabbi-Anneni A; Tabbi-Anneni H; Assan R Diabetes Care; 1982; 5 Suppl 2():63-6. PubMed ID: 6765544 [TBL] [Abstract][Full Text] [Related]
8. Impact of transfer from animal-source insulins to biosynthetic human insulin (rDNA E coli) in patients with diabetes mellitus. Garber AJ; Davidson JA; Krosnick A; Beaser RS; Anderson JH Clin Ther; 1991; 13(5):627-36. PubMed ID: 1799920 [TBL] [Abstract][Full Text] [Related]
9. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Rosenstock J; Park G; Zimmerman J; Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511 [TBL] [Abstract][Full Text] [Related]
10. A comparison of semisynthetic human NPH insulin and porcine NPH insulin in the treatment of insulin-dependent diabetes mellitus. Pedersen C; Høegholm A Diabet Med; 1987; 4(4):304-6. PubMed ID: 2956040 [TBL] [Abstract][Full Text] [Related]
11. Human (recombinant DNA) and porcine NPH insulins are unequally effective in diabetic patients. A comparative study using continuous blood glucose monitoring. Richard JL; Rodier M; Cavalié G; Mirouze J; Monnier L Acta Diabetol Lat; 1984; 21(3):211-7. PubMed ID: 6393670 [TBL] [Abstract][Full Text] [Related]
12. Immunologic improvement resulting from the transfer of animal insulin-treated diabetic subjects to human insulin (recombinant DNA). Fineberg SE; Galloway JA; Fineberg NS; Rathbun MJ Diabetes Care; 1982; 5 Suppl 2():107-13. PubMed ID: 6765519 [TBL] [Abstract][Full Text] [Related]
13. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin. Riccio A; Avogaro A; Valerio A; Zappella A; Tiengo A; Del Prato S Diabetes Care; 1994 Jun; 17(6):535-40. PubMed ID: 8082521 [TBL] [Abstract][Full Text] [Related]
14. A clinical comparison of purified bovine and purified porcine insulins. Olczak SA; Greenwood RH Postgrad Med J; 1985 Jan; 61(711):15-8. PubMed ID: 3887349 [TBL] [Abstract][Full Text] [Related]
15. Insulin allergy treated with human insulin (recombinant DNA). De Leeuw I; Delvigne C; Bekaert J Diabetes Care; 1982; 5 Suppl 2():168-70. PubMed ID: 6765530 [TBL] [Abstract][Full Text] [Related]
16. Receptor binding studies and clinical effects of human insulin (recombinant DNA): studies in patients with newly diagnosed type i diabetes, type II diabetes, insulin resistance (type A and type B), insulin antibodies, insulin allergy, and "brittle" diabetes. Schlüter KJ; Kerp L Diabetes Care; 1982; 5 Suppl 2():152-60. PubMed ID: 6765528 [TBL] [Abstract][Full Text] [Related]
17. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Raskin P; Klaff L; Bergenstal R; Hallé JP; Donley D; Mecca T Diabetes Care; 2000 Nov; 23(11):1666-71. PubMed ID: 11092290 [TBL] [Abstract][Full Text] [Related]
18. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Koivisto VA; Tuominen JA; Ebeling P Diabetes Care; 1999 Mar; 22(3):459-62. PubMed ID: 10097929 [TBL] [Abstract][Full Text] [Related]
19. Intermediate-acting insulin preparations: NPH and lente. Deckert T Diabetes Care; 1980; 3(5):623-6. PubMed ID: 7192205 [TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of human insulin (recombinant DNA)--regular, NPH, and mixtures--obtained by the Gerritzen method in healthy volunteers. Weinges K; Ehrhardt M; Nell G; Enzmann F Diabetes Care; 1982; 5 Suppl 2():67-70. PubMed ID: 6765545 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]